DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01712178 (ClinicalTrials.gov)	June 2012	14/6/2012	A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety	Study to Assess the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of a New Adalimumab Formulation in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: Adalimumab, current formulation;Biological: Adalimumab, new formulation	AbbVie (prior sponsor, Abbott)	NULL	Completed	18 Years	N/A	All	100	Phase 2	United States;Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01712178
(ClinicalTrials.gov)

June 2012

14/6/2012

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Study to Assess the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of a New Adalimumab Formulation in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Biological: Adalimumab, current formulation;Biological: Adalimumab, new formulation

AbbVie (prior sponsor, Abbott)

NULL

Completed

18 Years

N/A

All

100

Phase 2

United States;Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia